NeoGenomics, Inc. (NASDAQ:NEO) Stock Holdings Boosted by Arizona State Retirement System

Arizona State Retirement System grew its holdings in NeoGenomics, Inc. (NASDAQ:NEO) by 2.0% in the second quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 35,739 shares of the medical research company’s stock after purchasing an additional 708 shares during the period. Arizona State Retirement System’s holdings in NeoGenomics were worth $496,000 as of its most recent SEC filing.

Other hedge funds also recently modified their holdings of the company. TD Asset Management Inc raised its holdings in shares of NeoGenomics by 3.2% during the second quarter. TD Asset Management Inc now owns 203,646 shares of the medical research company’s stock worth $2,825,000 after acquiring an additional 6,400 shares in the last quarter. Banque Cantonale Vaudoise increased its stake in NeoGenomics by 10.2% during the second quarter. Banque Cantonale Vaudoise now owns 17,575 shares of the medical research company’s stock valued at $244,000 after acquiring an additional 1,633 shares during the period. Crossmark Global Holdings Inc. increased its stake in NeoGenomics by 2.9% during the second quarter. Crossmark Global Holdings Inc. now owns 29,494 shares of the medical research company’s stock valued at $409,000 after acquiring an additional 842 shares during the period. HighMark Wealth Management LLC increased its stake in NeoGenomics by 2,993.3% during the second quarter. HighMark Wealth Management LLC now owns 92,800 shares of the medical research company’s stock valued at $1,287,000 after acquiring an additional 89,800 shares during the period. Finally, Kopp Family Office LLC boosted its holdings in NeoGenomics by 5.6% during the second quarter. Kopp Family Office LLC now owns 944,775 shares of the medical research company’s stock valued at $13,104,000 after purchasing an additional 50,266 shares in the last quarter. Hedge funds and other institutional investors own 98.50% of the company’s stock.

Wall Street Analyst Weigh In

NEO has been the topic of a number of recent research reports. Needham & Company LLC reaffirmed a “buy” rating and set a $19.00 price objective on shares of NeoGenomics in a report on Tuesday, July 30th. Stephens restated an “overweight” rating and issued a $19.00 price objective on shares of NeoGenomics in a research report on Tuesday, July 30th. Finally, Benchmark restated a “buy” rating and issued a $18.00 price objective on shares of NeoGenomics in a research report on Tuesday, July 30th. Two investment analysts have rated the stock with a hold rating and nine have given a buy rating to the company’s stock. Based on data from MarketBeat, NeoGenomics currently has a consensus rating of “Moderate Buy” and an average price target of $19.89.

NeoGenomics Price Performance

NEO opened at $16.33 on Tuesday. The company has a quick ratio of 1.93, a current ratio of 2.01 and a debt-to-equity ratio of 0.37. NeoGenomics, Inc. has a 12 month low of $11.03 and a 12 month high of $21.22. The company has a fifty day simple moving average of $15.87 and a 200 day simple moving average of $14.93. The stock has a market cap of $2.09 billion, a P/E ratio of -24.74 and a beta of 1.19.

NeoGenomics (NASDAQ:NEO) last released its quarterly earnings data on Monday, July 29th. The medical research company reported $0.03 EPS for the quarter. NeoGenomics had a negative net margin of 12.50% and a negative return on equity of 2.72%. The business had revenue of $164.50 million during the quarter, compared to analysts’ expectations of $161.82 million. During the same quarter in the prior year, the company earned ($0.09) EPS. The firm’s quarterly revenue was up 12.0% on a year-over-year basis. On average, research analysts expect that NeoGenomics, Inc. will post -0.22 EPS for the current year.

NeoGenomics Company Profile

NeoGenomics, Inc operates a network of cancer-focused testing laboratories in the United States and the United Kingdom. It operates through Clinical Services and Advanced Diagnostics segments. The company offers testing services to hospitals, academic centers, pathologists, oncologists, clinicians, pharmaceutical companies, and clinical laboratories.